Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) is a biopharmaceutical company headquartered in Edison, New Jersey. Founded in 2013, the company focuses on developing advanced drug therapies for chronic liver diseases. Hepion's core mission is to enhance treatment options for liver conditions such as non-alcoholic steatohepatitis (NASH), viral hepatitis, and hepatocellular carcinoma (HCC).
The company's flagship product is Rencofilstat, a pan-cyclophilin inhibitor designed to target multiple pathological pathways involved in liver disease progression. This pleiotropic drug therapy has shown promising results in preclinical and clinical trials, including recently completed Phase I trials. Rencofilstat is currently being studied for its potential to address complex liver pathologies, including fibrosis and cancerous conditions associated with NASH and hepatitis.
Another significant development from Hepion is Tenofovir Exalidex, a lipid acyclic nucleoside phosphonate intended to deliver high intracellular concentrations of tenofovir diphosphate, an active antiviral agent. This drug aims to offer more effective treatment options for Hepatitis B patients.
Hepion Pharmaceuticals has also made headlines with its adoption of artificial intelligence (AI)-driven drug development, focusing on precision medicine for chronic diseases. Recent research has revealed that Rencofilstat may exert anti-cancer activity through mechanisms such as altering DNA accessibility, silencing oncogenes, and activating tumor suppressor genes.
The company was formerly known as ContraVir Pharmaceuticals, Inc. before rebranding to Hepion Pharmaceuticals in July 2019 to better align with its focus on liver disease therapies. With a commitment to cutting-edge research and development, Hepion Pharmaceuticals continues to advance its clinical programs and partnerships, offering hope to patients suffering from debilitating liver diseases.
On April 17, 2023, Hepion Pharmaceuticals (NASDAQ:HEPA) announced that an abstract regarding its lead drug candidate, rencofilstat, will be presented by Chief Scientific Officer Daren Ure, PhD, at the American Association for Cancer Research Annual Meeting in Orlando, Florida, from April 15-19, 2023. The presentation, titled Rencofilstat Exerts a Dominant Role in Synergistic Anti-PD1-Combination Effects in a Fatty Liver Model of Hepatocellular Carcinoma, is scheduled for April 18, 2023, from 9:00 AM to 12:30 PM ET. Rencofilstat is currently in Phase 2 clinical trials for treating non-alcoholic steatohepatitis (NASH) and has received Fast Track and Orphan Drug designations from the FDA for its potential applications. The company utilizes its proprietary AI platform, AI-POWR™, for precision medicine in identifying responsive NASH patients.
Hepion Pharmaceuticals (NASDAQ:HEPA) has appointed four renowned experts to its Scientific Advisory Board (SAB) as of March 30, 2023. This move enhances the company’s expertise in liver disease research and drug development. The new members are Dr. Rohit Loomba, Dr. Vlad Ratziu, Dr. Yury V. Popov, and Dr. Nikolai Naoumov, each bringing extensive backgrounds in hepatology.
Their experience will support Hepion's clinical programs for rencofilstat, aimed at treating NASH and HCC. Rencofilstat is currently in Phase 2 trials, with FDA Fast Track and Orphan Drug designations. Hepion also employs an AI platform, AI-POWR™, to optimize patient outcomes in its drug development.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced that CEO Robert Foster and SVP Patrick Mayo will present in the free webinar "How Artificial Intelligence is Changing Drug Discovery" on March 23, 2023, at 1:00 PM ET. They will showcase their AI-POWR™ platform, which enhances drug target selection and clinical study design for fibrotic diseases like NASH and HCC. The AI-POWR™ platform integrates extensive clinical data with publicly available multi-omic databases, identifying biomarkers for patient response to rencofilstat, Hepion's lead drug. This innovative approach aims to optimize ongoing clinical trials and improve patient outcomes in drug development.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced that Chief Medical Officer Todd Hobbs will present an update on the NASH clinical program for rencofilstat at the Global NASH Congress on March 3, 2023. The presentation will cover the ASCEND-NASH and ALTITUDE-NASH trials, focusing on timelines and progress. The ASCEND-NASH trial, involving 90 sites across North America and Europe, aims for complete enrollment within 12 months. The ALTITUDE-NASH trial reached full enrollment in December 2022, with topline results expected in Q2 2023. The FDA has granted Fast Track and Orphan Drug designations for rencofilstat, highlighting its potential for treating NASH and HCC.
FAQ
What is the current stock price of Hepion Pharmaceuticals (HEPA)?
What is the market cap of Hepion Pharmaceuticals (HEPA)?
What is the main focus of Hepion Pharmaceuticals?
What is Rencofilstat?
What other products is Hepion Pharmaceuticals developing?
Where is Hepion Pharmaceuticals headquartered?
When was Hepion Pharmaceuticals founded?
Has Rencofilstat completed any clinical trials?
Does Hepion Pharmaceuticals use any advanced technologies in its research?
What was the former name of Hepion Pharmaceuticals?
Why did the company change its name?
Is Hepion Pharmaceuticals involved in any partnerships?
